First Subject Receives Initial Treatment in Innovent's Phase III Trial (Neoshot) Evaluating IBI310 (Anti-CTLA-4) with Sintilimab in Pre-Surgery Treatment for High Microsatellite Instability/Mismatch Repair Deficient Colon Cancer.

Tectonic Therapeutics Commences First-Stage Clinical Trial Evaluating TX45 in Category II Lung High Blood Pressure among Subjects Having Conserved Ejection Fraction Cardiac Insufficiency.

FDA Regulators Greenlight Merck's Novel WINREVAIR™ (sotatercept-csrk) Therapy for Treating Pulmonary Arterial Hypertension in Adult Patients.

Pharmacodynamics is the study of the biochemical and physiological effects of drugs on the body, including the mechanisms of action and the relationship between drug concentration and effect.

Atamyo Pharma Secures Approval from European Regulators to Commence Human Trials of ATA-200, Their Innovative Genetic Treatment for Limb-Girdle Muscular Dystrophy 2C/R5.

Gut-Derived Hormone Cholesin Found to Regulate Cholesterol Metabolism.

CinFina Pharma Reveals US Health Authority's Approval for Early-Stage Drug Trial and Commencement of Dosing in Initial Human Subjects for its Obesity Medication, CIN-110.

Pharmacokinetics (PK) is the study of how a drug moves through the body, which includes the processes of absorption, distribution, metabolism, and excretion.

Astellas Pharma Inc. announced that Japan's Ministry of Health, Labour and Welfare approved VYLOY™ (zolbetuximab), an anti-CLDN18.2 drug, for advanced and inoperable metastatic stomach cancer patients positive for CLDN18.2.

Curated Selection of the Latest Developments in the Field of New Drug Research and Development: A Quick Overview of Progress in New Drug R&D, Pharmaceutical Deals, and Cutting-Edge Technologies from This Week.

Initial enrollment of patients with stomach and esophageal cancer has begun for a second-stage mixed studies trial, utilizing Affibody's ABY-025 diagnostic tool for positron emission tomography.

On March 22, Johnson & Johnson announced FDA approval of OPSYNVI®, their new drug for treating WHO Group 1 PAH and class II-III PAH in adults. OPSYNVI® combines macitentan and tadalafil in a single tablet.